All HHS Contracts — June 25, 2026

Leidos Biomedical Research Inc. secured a $63.1M cost-plus-fixed-fee delivery order from NIH/NCI for R&D facility operations, reflecting ongoing federal investment in cancer research infrastructure. The contract's full-and-open competition suggests Leidos' operational expertise in life sciences R&D (NAICS 541715) sustains a competitive edge in civilian biomedical contracts.

The contract runs only one year (ending August 30, 2020) with no options exercised against a $67.1M base+options ceiling, implying NIH may have reprioritized or delayed follow-on spending. Future NIH budget uncertainties under a continuing resolution could delay re-competes, creating a potential gap in Leidos' civilian revenue stream.

Leidos relies on a single $63.1M delivery order from NIH NCI for civilian R&D revenue, with no diversification across other civilian agencies in this period; a 1-year performance window increases vulnerability to NIH budget shifts or re-compete delays.

Full-and-open competition with no set-aside suggests Leidos won on merit, but peers (e.g., Battelle, SAIC, HII) could bid on future NIH NCI facility operations contracts, pressuring win rates or margins.

Leidos Biomedical's $63.1M win confirms NIH's continuing reliance on GOCO contractors for R&D facility management, a niche with high barriers to entry (NAICS 541715). Follow-on awards or task orders under the IDIQ vehicle could expand revenue.

The $63.1M award to Leidos for NIH/NCI facility operations, the only contract in this period, reinforces that civilian agency R&D spending on cancer research continues at a steady pace but lacks the acceleration seen in DOD modernization or defense health contracts.

{"entity"=>"Leidos Holdings, Inc. (LDOS)", "reason"=>"The $63.1M NIH contract is a steady but non-transformative revenue contributor; risk of revenue gap if follow-on awards are delayed or lost to a competitor.", "trigger"=>"NIH NCI re-compete solicitation release (expected by Q2 2027) or option exercise announcement"}